Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome
Shin Hye Kim ; So-Hee Eun ; Heung Dong Kim ; Baik-Lin Eun ; Joon Soo Lee ; Young-Mock Lee ; Jung Hye Byeon ; Eun Ji Kwon ; Hoon-Chul Kang
Seizure - European Journal of Epilepsy, Vol.21(4) : 288~291, 2012
Seizure - European Journal of Epilepsy
PURPOSE: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS).
METHODS: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period.
RESULTS: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency.
CONCLUSIONS: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS.